Dr. Daniel Reif Greenwald, MD

Dr. Greenwald practices at UCLA Medical Plaza in Santa Barbara, California.

Dr. Greenwald's NPI, 1235240987, was assigned on August 31, 2006. Dr. Greenwald graduated from Stanford University School Of Medicine in 2000. Dr. Greenwald holds California license A75508.

Dr. Greenwald's primary practice is UCLA Medical Plaza, at 309 W Quinto St, Santa Barbara, CA 93105 in Santa Barbara County. The practice phone is (310) 794-1276.

Dr. Greenwald's primary practice is UCLA Medical Plaza in Santa Barbara, California. Dr. Greenwald is also affiliated with Santa Barbara Cottage Hospital. The medical group on file is UCLA Medical Group. Dmand AI also links Dr. Greenwald to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Greenwald practices, 5 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Greenwald's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Greenwald is board certified in hematology by the American Board of Internal Medicine. Dr. Greenwald is licensed in California.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, fluid and electrolyte imbalances, immune deficiency disease, lung cancer and lymphoma among the conditions Dr. Greenwald treats.

CMS data shows 101,167 Medicare services from Dr. Greenwald across 37 procedure codes in 2024, for 881 Medicare patients. Medicare paid $3,567,353 for them.

CMS counts 881 Medicare patients who saw Dr. Greenwald in 2024. The largest group is 75 to 84, with 388 patients. 73% of them have high cholesterol, and 63% have high blood pressure. 6% are also on Medicaid. Their average risk score is 1.85, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Greenwald's median patient age at 73, with 57% women.

In 2024, Dr. Greenwald wrote 473 Medicare Part D claims for 139 patients. 77% of them were for generic drugs. CMS names the drug for 217 of them, across 8 drugs with 11 or more claims each, at $125,640 in total drug cost. In 2023, CMS named 207 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Greenwald for performance year 2024, reported as part of a group. Dr. Greenwald accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Greenwald as offering telehealth.

Dmand AI links 7 papers to Dr. Greenwald, published from 2013 to 2023. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols. Dr. Greenwald's most frequent co-authors are Leonard M. Klein, David Jacob Andorsky, MD and Paul Michael Barr, MD.

Dmand AI links Dr. Greenwald to 6 clinical trials, 2 of them phase 1 studies. 3 are still active or recruiting. Conditions studied include Multiple Myeloma, Blood Protein Disorders and Leukemia, Lymphocytic, Chronic, B-Cell. Seagen Inc. sponsors the most, 2.

CMS Open Payments shows 479 general payments to Dr. Greenwald from 56 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 55% of the total. Genentech, Inc. paid the most, $121,707. It also lists 13 research payments totaling $62,818 from 2016 to 2024.

Dr. Greenwald graduated from Stanford University School Of Medicine in 2000.

Dr. Greenwald is in network with 13 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.